Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cooper Companies, Inc. filings document a Nasdaq-listed medical device company with common stock trading under the symbol COO. Its regulatory disclosures include Form 8-K reports on quarterly results, board and officer changes, annual meeting voting results, and material definitive agreements, including amendments to term loan arrangements.
Proxy materials describe director elections, board committee matters, executive compensation, shareholder proposals, and governance practices. Together, the filings record operating and financial disclosures for CooperVision and CooperSurgical, capital structure information, debt arrangements, stockholder voting mechanics, and risk and governance topics relevant to the company’s contact lens, fertility, and women’s healthcare businesses.
Cooper Companies director Barbara Carbone reported routine equity compensation activity. On April 1, 2026, she exercised 3,050 Restricted Stock Units, converting them into 3,050 shares of Common Stock at a stated price of $0.00 per share, reflecting non-cash vesting rather than a market purchase.
On the same date, she also received a new grant of 3,779 Restricted Stock Units, each representing a right to acquire one share of Common Stock. The award has no expiration date; the units will either vest or be forfeited over time. Following these transactions, she directly holds 3,050 shares of Common Stock and 3,779 Restricted Stock Units.
Rosebrough Walter M Jr reported acquisition or exercise transactions in this Form 4 filing.
COOPER COMPANIES, INC. director Walter M. Rosebrough Jr received a grant of 3,779 Restricted Stock Units on April 1, 2026 as equity compensation. Each unit represents one share of common stock.
The RSUs are scheduled to vest on April 1, 2027 and have no expiration date; they will either vest or be forfeited. Following this award, he holds 3,779 RSUs directly, and there were no open-market purchases or sales in this filing.
COOPER COMPANIES, INC. director Teresa S. Madden reported routine equity compensation activity involving restricted stock units and common shares. On April 1, 2026, she exercised 3,322 restricted stock units into 3,322 shares of common stock at $0.00 per share, increasing her direct common stock holdings to 15,679 shares.
On the same date, she received a new grant of 3,779 restricted stock units, each representing one share of common stock, scheduled to vest on April 1, 2027. A related footnote explains that this award has no expiration date and that the units will either vest or be forfeited, underscoring their service-based nature rather than being a market transaction.
Cooper Companies director Cynthia L. Lucchese reported compensation-related equity activity. On April 1, 2026, she exercised 3,322 Restricted Stock Units, acquiring the same number of common shares at a stated price of $0.00 per share. She also received a new grant of 3,779 Restricted Stock Units, which are scheduled to vest on April 1, 2027. After these transactions, she holds 12,767 shares of Cooper Companies common stock directly. A footnote explains the RSU award has no expiration date and that units will either vest or be forfeited.
Cooper Companies director Lawrence Erik Kurzius reported equity compensation activity involving restricted stock units and common stock. He exercised 3,322 Restricted Stock Units into 3,322 shares of Common Stock at a stated price of $0.00 per share, converting a derivative award into stock ownership.
He also received a new grant of 3,779 Restricted Stock Units, which have no expiration date and will either vest or be forfeited according to the award terms. Following these transactions, he directly owns 11,099 shares of Common Stock and holds 3,779 Restricted Stock Units, reflecting routine compensation-related acquisitions rather than open-market buying or selling.
Cooper Companies, Inc. ownership filing amended: The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0%. The amendment explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with disaggregated reporting by subsidiaries. filing signed March 26, 2026.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.
CooperCompanies reported a solid fiscal first quarter 2026, with revenue of $1.024 billion, up 6% from a year earlier and 3% organically. Growth was led by CooperVision, where revenue rose 8% to $695.1 million, while CooperSurgical revenue increased 3% to $329.0 million.
GAAP diluted EPS grew to $0.66, up 27%, and non-GAAP diluted EPS rose to $1.10, up 20%, as operating margin improved to 21% on a GAAP basis and 27% on a non-GAAP basis. Free cash flow was $158.7 million, supporting $92.5 million of share repurchases. The company raised its fiscal 2026 outlook, guiding total revenue to $4.306–$4.346 billion, non-GAAP EPS to $4.58–$4.66, and free cash flow to $600–$625 million.
CooperCompanies presents its 2026 annual meeting proxy, highlighting 2025 results, governance and executive pay. Stockholders are asked to elect nine directors, ratify KPMG as auditor, and approve a non-binding say-on-pay vote, with the Board recommending “FOR” on all three proposals.
In fiscal 2025, revenue reached $4.09 billion, up 5% from 2024, with GAAP diluted EPS of $1.87, non-GAAP diluted EPS of $4.13, and free cash flow of about $434 million. The company repurchased $290.1 million of stock, roughly 4.1 million shares, and the Board expanded the share repurchase authorization to $2 billion, leaving nearly $1 billion available.
Cooper completed major restructuring and integration work, recording approximately $89 million in related charges and expecting about $50 million in annual pre-tax savings from fiscal 2026. The proxy emphasizes an independent Board, robust committee structure, strong ESG and cybersecurity oversight, and a pay-for-performance program where most executive compensation is performance-based.
CooperCompanies executive Brian G. Andrews, EVP, CFO & Treasurer, reported an amended stock option award. The filing corrects the number of shares issuable under a previously reported option grant to 41,563 shares of common stock at an exercise price of $99.08 per share.
The options were granted on 12/10/2024, are held directly, and expire on 12/10/2034. They vest at 25% per year over four years starting on the grant date, reflecting time-based equity compensation rather than an open-market stock purchase or sale.